AI Article Synopsis

  • End-of-life (EOL) discussions can lead to lower healthcare costs and less aggressive treatment in the final days for cancer patients.
  • These conversations help reduce the use of emergency care, intensive care, and chemotherapy near death, while increasing the likelihood of hospice care and deaths outside of hospitals.
  • Starting these discussions at least 30 days before death is linked to better outcomes, highlighting the need for healthcare providers to engage patients earlier about their treatment preferences.

Article Abstract

Background: Aggressive end-of-life (EOL) care is associated with lower quality of life and greater regret about treatment decisions. Higher EOL costs are also associated with lower quality EOL care. Advance care planning and goals-of-care conversations ("EOL discussions") may influence EOL health-care utilization and costs among persons with cancer.

Objective: To describe associations among EOL discussions, health-care utilization and place of death, and costs in persons with advanced cancer and explore variation in study measures.

Methods: A systematic review was conducted using PubMed, Embase, and CINAHL. Twenty quantitative studies published between January 2012 and January 2019 were included.

Results: End-of-life discussions are associated with lower health-care costs in the last 30 days of life (median US$1048 vs US$23482; < .001); lower likelihood of acute care at EOL (odds ratio [(OR] ranging 0.43-0.69); lower likelihood of intensive care at EOL (ORs ranging 0.26-0.68); lower odds of chemotherapy near death (ORs 0.41, 0.57); lower odds of emergency department use and shorter length of hospital stay; greater use of hospice (ORs ranging 1.79 to 6.88); and greater likelihood of death outside the hospital. Earlier EOL discussions (30+ days before death) are more strongly associated with less aggressive care outcomes than conversations occurring near death.

Conclusions: End-of-life discussions are associated with less aggressive, less costly EOL care. Clinicians should initiate these discussions with patients having cancer earlier to better align care with preferences.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711813PMC
http://dx.doi.org/10.1177/1049909119848148DOI Listing

Publication Analysis

Top Keywords

end-of-life discussions
12
health-care utilization
12
costs persons
12
eol care
12
associated lower
12
eol
9
discussions health-care
8
utilization costs
8
persons advanced
8
advanced cancer
8

Similar Publications

Understanding the values and origin of fundamental physical constants, one of the grandest challenges in modern science, has been discussed in particle physics, astronomy and cosmology. More recently, it was realized that fundamental constants have a biofriendly window set by life processes involving motion and flow. This window is related to intrinsic fluid properties such as energy and length scales in condensed matter set by fundamental constants.

View Article and Find Full Text PDF

Ferroptosis, an iron-dependent form of programmed cell death driven by oxidative stress, plays a crucial role in the progression of Alzheimer's disease (AD). Aging diminishes antioxidant systems that maintain iron homeostasis, particularly affecting the glutathione peroxidase (GPX) system, leading to increased ferroptosis and exacerbated neurodegeneration and neuroinflammation in AD. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key transcription factor regulating genes involved in antioxidant defense and ferroptosis.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is a common progressive neurodegenerative disorder, and the vast majority of cases occur in elderly patients. Recently, the accumulation of Aβ and tau proteins has drawn considerable attention in AD research. This review explores the multifaceted interactions between these proteins and their contribution to the pathological landscape of AD, encompassing synaptic dysfunction, neuroinflammation, and PANoptosis.

View Article and Find Full Text PDF

Background: Hallmark pathologies of Alzheimer's Disease (AD) include the accumulation of both extracellular amyloid and intracellular tau proteins. While a significant body of knowledge exists surrounding the role of the protein aggregates in the context of AD, research supporting these as targets for therapeutic development have yielded inconsistent findings. One significant barrier is the inability to restore cognitive function despite the successful clearance of these proteins.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!